Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
Birgit Geoerger(Université Paris-Saclay), Hyoung Jin Kang(Seoul National University Children's Hospital), Michal Yalon-Oren(Sheba Medical Center), Lynley V. Marshall(Royal Marsden Hospital), Catherine Vézina(McGill University Health Centre), Alberto S. Pappo(St. Jude Children's Research Hospital), Theodore W. Laetsch(The University of Texas Southwestern Medical Center), Antônio Sérgio Petrilli(Universidade Federal de São Paulo), Martin Ebinger(University Children's Hospital Tübingen), Jacek Toporski(Skåne University Hospital), Julia Glade Bender(Columbia University Irving Medical Center), Wayne Nicholls(Queensland Children’s Hospital), Elizabeth Fox(Children's Hospital of Philadelphia), Steven G. DuBois(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Margaret E. Macy(Center for Cancer and Blood Disorders), Susan L. Cohn(University of Chicago), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Navin Pinto(Seattle Children's Hospital)
Cited by 337
Abstract
Related Papers
No related papers found
Powered by citation graph analysis